HEALTHCARE SERVICES GROUP INC
HCSGDrugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How HCSG's past catalysts played out
marimastat
Lung Cancer
33525
Tinea Pedis
Product 55394
Bacterial Vaginosis
Test Product 49778
Seborrheic Dermatitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
marimastat | Phase 3 | Lung Cancer | - | - |
33525 | Phase 3 | Tinea Pedis | - | - |
Product 55394 | Phase 3 | Bacterial Vaginosis | - | - |
Test Product 49778 | Phase 2 | Seborrheic Dermatitis | - | - |
Frequently asked questions
What is in HEALTHCARE SERVICES GROUP INC's drug pipeline?→
CatalystAlert tracks 4 drug candidates in HEALTHCARE SERVICES GROUP INC's (HCSG) pipeline across Phase 3, Phase 2. Its lead program is marimastat (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is HEALTHCARE SERVICES GROUP INC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for HEALTHCARE SERVICES GROUP INC (HCSG) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track HCSG biotech catalysts?→
Add HCSG to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow HEALTHCARE SERVICES GROUP INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.